Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

An Injectable Hydrogel Sustains Low-Dose Intra-Articular Glucocorticoid Exposure to Protect Cartilage in Osteoarthritis.

Created on 01 Oct 2026

Authors

Xiaoyue Li, Dong Zhu, Jingyu Zhang, Jing Lyu, Chunyu Zhao, Lucy Boyi Wang, Peisheng Jin, Rijian Song, Qiang Li, Wenxin Wang

Published in

Acta biomaterialia. Sep 30, 2026. Epub Sep 30, 2026.

Abstract

Intra-articular glucocorticoid (GC) injections provide rapid symptomatic relief in osteoarthritis (OA). However, repeated administration of conventional triamcinolone acetonide (TA) suspensions can generate recurrent high local drug exposure, which may contribute to cartilage degeneration. Although extended-release TA formulations have been developed to reduce burst exposure, achieving prolonged and stable intra-articular drug retention while preserving cartilage structure remains challenging. Here we report an injectable hyaluronic acid (HA) hydrogel that forms a stable intra-articular depot to sustain delivery of TA and control local GC exposure kinetics. Sustained low-dose GC exposure modulates macrophage-associated inflammatory responses, suppresses pro-inflammatory cytokine production, and preserves chondrocyte mitochondrial homeostasis under inflammatory stress. In both murine and load-bearing large animal goat OA models, TA-loaded HA hydrogel treatment improves functional performance, reduces synovial inflammation, and preserves cartilage structure and matrix integrity, as demonstrated by enhanced gait or mechanical pain thresholds and higher MRI-based MOCART 2.0 scores. Our findings indicate that tuning intra-articular GC pharmacokinetics can enhance therapeutic durability while promoting structural joint preservation in OA. STATEMENT OF SIGNIFICANCE: Intra-articular glucocorticoids are widely used in osteoarthritis, yet their clinical value is limited by rapid clearance, repeated dosing, and harmful peak exposure. This work introduces an injectable hyaluronic acid hydrogel that transforms glucocorticoid therapy from a short-lived anti-inflammatory injection into a controlled, cartilage-protective treatment. By establishing a stable intra-articular drug depot, the hydrogel reshapes local glucocorticoid exposure, suppresses destructive joint inflammation, promotes a reparative microenvironment, and preserves chondrocyte and matrix homeostasis. Importantly, these benefits were demonstrated not only in mice but also in a load-bearing goat model, highlighting a clinically relevant biomaterial strategy for safer and more durable structure-modifying osteoarthritis therapy.

PMID:
42815820
Bibliographic data and abstract were imported from PubMed on 01 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 21
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement